Final data analysis by the PARASOL collaboration with Dimerix

9 October 2025

Australian biotech Dimerix Limited (ASX: DXB), which has a Phase III clinical asset in kidney disease, announced that the final data analysis by the PARASOL collaboration with Dimerix has been received.

This analysis of observational data from major renal registries was conducted to provide Dimerix with further rationale to support the choice of proteinuria endpoints at 104 weeks for the ACTION3 study for potential marketing approval in the USA. In addition, the analysis explored the relationship between proteinuria endpoints at 12 months and the subsequent risk of kidney failure and eGFR endpoints to support a potential application for Accelerated Approval.

The PARASOL analysis used a patient population that emulated the ACTION3 clinical study population (ie, using the major ACTION3 inclusion and exclusion criteria). Pleasingly the results of this analysis are generally consistent with the broader PARASOL analysis conducted in 2024 that supported the use of proteinuria as an endpoint for FSGS clinical trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK